Prospect and progress of gene therapy in treating atherosclerosis

Bibliography

• Perk J, De Backer G, Gohlke H, et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J 2012;33:1635-701
   PubMed Web of Science ®Google Scholar
• Yla-Herttuala S, Nikkari T, Hirvonen J, et al. Biochemical composition of coronary arteries in Finnish children. Arteriosclerosis 1986;6:230-6
   PubMedGoogle Scholar
• Usifo E, Leigh SE, Whittall RA, et al. Low-density lipoprotein receptor gene familial hypercholesterolemia variant database: update and pathological assessment. Ann Hum Genet 2012;76:387-401
   PubMed Web of Science ®Google Scholar
• Kankkonen HM, Vahakangas E, Marr RA, et al. Long-term lowering of plasma cholesterol levels in LDL-receptor-deficient WHHL rabbits by gene therapy. Mol Ther 2004;9:548-56
   PubMed Web of Science ®Google Scholar
• Kassim SH, Li H, Bell P, et al. Adeno-associated virus serotype 8 gene therapy leads to significant lowering of plasma cholesterol levels in humanized mouse models of homozygous and heterozygous familial hypercholesterolemia. Hum Gene Ther 2013;24:19-26
   PubMed Web of Science ®Google Scholar
• Grossman M, Rader DJ, Muller DW, et al. A pilot study of ex vivo gene therapy for homozygous familial hypercholesterolaemia. Nat Med 1995;1:1148-54
   PubMed Web of Science ®Google Scholar
• Van Craeyveld E, Jacobs F, Gordts SC, De Geest B. Gene therapy for familial hypercholesterolemia. Curr Pharm Des 2011;17:2575-91
   PubMed Web of Science ®Google Scholar
• Park SW, Moon YA, Horton JD. Post-transcriptional regulation of low density lipoprotein receptor protein by proprotein convertase subtilisin/kexin type 9a in mouse liver. J Biol Chem 2004;279:50630-8
   PubMed Web of Science ®Google Scholar
• Chan JC, Piper DE, Cao Q, et al. A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates. Proc Natl Acad Sci USA 2009;106:9820-5
   PubMed Web of Science ®Google Scholar
• Zhang L, McCabe T, Condra JH, et al. An anti-PCSK9 antibody reduces LDL-cholesterol on top of a statin and suppresses hepatocyte SREBP-regulated genes. Int J Biol Sci 2012;8:310-27
   PubMed Web of Science ®Google Scholar
• Liang H, Chaparro-Riggers J, Strop P, et al. Proprotein convertase substilisin/kexin type 9 antagonism reduces low-density lipoprotein cholesterol in statin-treated hypercholesterolemic nonhuman primates. J Pharmacol Exp Ther 2012;340:228-36
   PubMed Web of Science ®Google Scholar
• Yamamoto T, Harada-Shiba M, Nakatani M, et al. Cholesterol-lowering Action of BNA-based Antisense Oligonucleotides Targeting PCSK9 in Atherogenic Diet-induced Hypercholesterolemic Mice. Mol Ther Nucleic Acids 2012;1:e22
   PubMedGoogle Scholar
• Lindholm MW, Elmen J, Fisker N, et al. PCSK9 LNA antisense oligonucleotides induce sustained reduction of LDL cholesterol in nonhuman primates. Mol Ther 2012;20:376-81
   PubMed Web of Science ®Google Scholar
• Frank-Kamenetsky M, Grefhorst A, Anderson NN, et al. Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates. Proc Natl Acad Sci USA 2008;105:11915-20
   PubMed Web of Science ®Google Scholar
• Ding Q, Strong A, Patel KM, et al. Permanent alteration of PCSK9 with in vivo CRISPR-Cas9 genome editing. Circ Res 2014;115:488-92
   PubMed Web of Science ®Google Scholar
• Rocha CS, Wiklander OP, Larsson L, et al. RNA therapeutics inactivate PCSK9 by inducing a unique intracellular retention form. J Mol Cell Cardiol 2015;82:186-93
   PubMed Web of Science ®Google Scholar
• Crooke RM, Graham MJ, Lemonidis KM, et al. An apolipoprotein B antisense oligonucleotide lowers LDL cholesterol in hyperlipidemic mice without causing hepatic steatosis. J Lipid Res 2005;46:872-84
   PubMed Web of Science ®Google Scholar
• Tadin-Strapps M, Peterson LB, Cumiskey AM, et al. siRNA-induced liver ApoB knockdown lowers serum LDL-cholesterol in a mouse model with human-like serum lipids. J Lipid Res 2011;52:1084-97
   PubMed Web of Science ®Google Scholar
• Zimmermann TS, Lee AC, Akinc A, et al. RNAi-mediated gene silencing in non-human primates. Nature 2006;441:111-14
   PubMed Web of Science ®Google Scholar
• Maczuga P, Lubelski J, van Logtenstein R, et al. Embedding siRNA sequences targeting apolipoprotein B100 in shRNA and miRNA scaffolds results in differential processing and in vivo efficacy. Mol Ther 2013;21:217-27
   PubMed Web of Science ®Google Scholar
• Khoo B, Roca X, Chew SL, et al. Antisense oligonucleotide-induced alternative splicing of the APOB mRNA generates a novel isoform of APOB. BMC Mol Biol 2007;8:3
   PubMed Web of Science ®Google Scholar
• Disterer P, Al-Shawi R, Ellmerich S, et al. Exon skipping of hepatic APOB pre-mRNA with splice-switching oligonucleotides reduces LDL cholesterol in vivo. Mol Ther 2013;21:602-9
   PubMed Web of Science ®Google Scholar
• Schonfeld G. Familial hypobetalipoproteinemia. J Lipid Res 2003;44:878-83
   PubMed Web of Science ®Google Scholar
• Kahn JA, Glueck CJ. Familial hypobetalipoproteinemia. Absence of atherosclerosis in a postmortem study. JAMA 1978;240:47-8
   PubMed Web of Science ®Google Scholar
• Pollin TI, Damcott CM, Shen H, et al. A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection. Science 2008;322:1702-5
   PubMed Web of Science ®Google Scholar
• Clavey V, Lestavel-Delattre S, Copin C, et al. Modulation of lipoprotein B binding to the LDL receptor by exogenous lipids and apolipoproteins CI, CII, CIII, and E. Arterioscler Thromb Vasc Biol 1995;15:963-71
   PubMed Web of Science ®Google Scholar
• Yao Z, Wang Y. Apolipoprotein C-III and hepatic triglyceride-rich lipoprotein production. Curr Opin Lipidol 2012;23:206-12
   PubMed Web of Science ®Google Scholar
• Kawakami A, Aikawa M, Alcaide P, et al. Apolipoprotein CIII induces expression of vascular cell adhesion molecule-1 in vascular endothelial cells and increases adhesion of monocytic cells. Circulation 2006;114:681-7
   PubMed Web of Science ®Google Scholar
• Zheng C, Azcutia V, Aikawa E, et al. Statins suppress apolipoprotein CIII-induced vascular endothelial cell activation and monocyte adhesion. Eur Heart J 2013;34:615-24
   PubMed Web of Science ®Google Scholar
• Graham MJ, Lee RG, Bell TAIII, et al. Antisense oligonucleotide inhibition of apolipoprotein C-III reduces plasma triglycerides in rodents, nonhuman primates, and humans. Circ Res 2013;112:1479-90
   PubMed Web of Science ®Google Scholar
• Yamamoto T, Obika S, Nakatani M, et al. Locked nucleic acid antisense inhibitor targeting apolipoprotein C-III efficiently and preferentially removes triglyceride from large very low-density lipoprotein particles in murine plasma. Eur J Pharmacol 2014;723:353-9
   PubMed Web of Science ®Google Scholar
• Lagos-Quintana M, Rauhut R, Yalcin A, et al. Identification of tissue-specific microRNAs from mouse. Curr Biol 2002;12:735-9
   PubMed Web of Science ®Google Scholar
• Esau C, Davis S, Murray SF, et al. miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab 2006;3:87-98
   PubMed Web of Science ®Google Scholar
• Elmen J, Lindow M, Schutz S, et al. LNA-mediated microRNA silencing in non-human primates. Nature 2008;452:896-9
   PubMed Web of Science ®Google Scholar
• Lanford RE, Hildebrandt-Eriksen ES, Petri A, et al. Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science 2010;327:198-201
   PubMed Web of Science ®Google Scholar
• Rayner KJ, Suarez Y, Davalos A, et al. MiR-33 contributes to the regulation of cholesterol homeostasis. Science 2010;328:1570-3
   PubMed Web of Science ®Google Scholar
• Najafi-Shoushtari SH, Kristo F, Li Y, et al. MicroRNA-33 and the SREBP host genes cooperate to control cholesterol homeostasis. Science 2010;328:1566-9
   PubMed Web of Science ®Google Scholar
• Rayner KJ, Esau CC, Hussain FN, et al. Inhibition of miR-33a/b in non-human primates raises plasma HDL and lowers VLDL triglycerides. Nature 2011;478:404-7
   PubMed Web of Science ®Google Scholar
• Goedeke L, Salerno A, Ramirez CM, et al. Long-term therapeutic silencing of miR-33 increases circulating triglyceride levels and hepatic lipid accumulation in mice. EMBO Mol Med 2014;6:1133-41
   PubMed Web of Science ®Google Scholar
• Meiler S, Baumer Y, Toulmin E, et al. MicroRNA 302a is a novel modulator of cholesterol homeostasis and atherosclerosis. Arterioscler Thromb Vasc Biol 2015;35:323-31
   PubMed Web of Science ®Google Scholar
• Soh J, Iqbal J, Queiroz J, et al. MicroRNA-30c reduces hyperlipidemia and atherosclerosis in mice by decreasing lipid synthesis and lipoprotein secretion. Nat Med 2013;19:892-900
   PubMed Web of Science ®Google Scholar
• Vickers KC, Shoucri BM, Levin MG, et al. MicroRNA-27b is a regulatory hub in lipid metabolism and is altered in dyslipidemia. Hepatology 2013;57:533-42
   PubMed Web of Science ®Google Scholar
• Vickers KC, Landstreet SR, Levin MG, et al. MicroRNA-223 coordinates cholesterol homeostasis. Proc Natl Acad Sci USA 2014;111:14518-23
   PubMed Web of Science ®Google Scholar
• Yang L, Chu Y. Wang Y, et al. siRNA-mediated silencing of Wnt5a regulates inflammatory responses in atherosclerosis through the MAPK/NF-kappaB pathways. Int J Mol Med 2014;34:1147-52
   PubMed Web of Science ®Google Scholar
• Sun X, He S, Wara AK, et al. Systemic delivery of microRNA-181b inhibits nuclear factor-kappaB activation, vascular inflammation, and atherosclerosis in apolipoprotein E-deficient mice. Circ Res 2014;114:32-40
   PubMed Web of Science ®Google Scholar
• Inoue S, Egashira K, Ni W, et al. Anti-monocyte chemoattractant protein-1 gene therapy limits progression and destabilization of established atherosclerosis in apolipoprotein E-knockout mice. Circulation 2002;106:2700-6
   PubMed Web of Science ®Google Scholar
• Zhong L, Chen WQ, Ji XP, et al. Dominant-negative mutation of monocyte chemoattractant protein-1 prevents vulnerable plaques from rupture in rabbits independent of serum lipid levels. J Cell Mol Med 2008;12:2362-71
   PubMed Web of Science ®Google Scholar
• Liu XL, Zhang PF, Ding SF, et al. Local gene silencing of monocyte chemoattractant protein-1 prevents vulnerable plaque disruption in apolipoprotein E-knockout mice. PLoS ONE 2012;7:e33497
   PubMed Web of Science ®Google Scholar
• Galis ZS, Sukhova GK, Lark MW, et al. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 1994;94:2493-503
   PubMed Web of Science ®Google Scholar
• Muller A, Kramer SD, Meletta R, et al. Gene expression levels of matrix metalloproteinases in human atherosclerotic plaques and evaluation of radiolabeled inhibitors as imaging agents for plaque vulnerability. Nucl Med Biol 2014;41:562-9
   PubMed Web of Science ®Google Scholar
• Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res 2003;92:827-39
   PubMed Web of Science ®Google Scholar
• Rouis M, Adamy C, Duverger N, et al. Adenovirus-mediated overexpression of tissue inhibitor of metalloproteinase-1 reduces atherosclerotic lesions in apolipoprotein E-deficient mice. Circulation 1999;100:533-40
   PubMed Web of Science ®Google Scholar
• de Vries MR, Niessen HW, Lowik CW, et al. Plaque rupture complications in murine atherosclerotic vein grafts can be prevented by TIMP-1 overexpression. PLoS ONE 2012;7:e47134
   Google Scholar
• Lemaitre V, Soloway PD, D’Armiento J. Increased medial degradation with pseudo-aneurysm formation in apolipoprotein E-knockout mice deficient in tissue inhibitor of metalloproteinases-1. Circulation 2003;107:333-8
   PubMed Web of Science ®Google Scholar
• Johnson JL, Baker AH, Oka K, et al. Suppression of atherosclerotic plaque progression and instability by tissue inhibitor of metalloproteinase-2: involvement of macrophage migration and apoptosis. Circulation 2006;113:2435-44
   PubMed Web of Science ®Google Scholar
• Di Gregoli K, George SJ, Jackson CL, et al. Tissue inhibitor of metalloproteinase (TIMP)-2 retards MMP-14-dependent monocyte/macrophage invasion and modulates atherosclerosis. Atherosclerosis 2014;237:e7
   Google Scholar
• Stohr R, Cavalera M, Menini S, et al. Loss of TIMP3 exacerbates atherosclerosis in ApoE null mice. Atherosclerosis 2014;235:438-43
   PubMed Web of Science ®Google Scholar
• Johnson JL, Jenkins NP, Huang WC, et al. Relationship of MMP-14 and TIMP-3 expression with macrophage activation and human atherosclerotic plaque vulnerability. Mediators Inflamm 2014;2014:276457
   PubMed Web of Science ®Google Scholar
• Casagrande V, Menghini R, Menini S, et al. Overexpression of tissue inhibitor of metalloproteinase 3 in macrophages reduces atherosclerosis in low-density lipoprotein receptor knockout mice. Arterioscler Thromb Vasc Biol 2012;32:74-81
   PubMed Web of Science ®Google Scholar
• Moore KW, O’Garra A, de Waal Malefyt R, et al. Interleukin-10. Annu Rev Immunol 1993;11:165-90
   PubMed Web of Science ®Google Scholar
• Han X, Kitamoto S, Lian Q, et al. Interleukin-10 facilitates both cholesterol uptake and efflux in macrophages. J Biol Chem 2009;284:32950-8
   PubMed Web of Science ®Google Scholar
• Von Der Thusen JH, Kuiper J, Fekkes ML, et al. Attenuation of atherogenesis by systemic and local adenovirus-mediated gene transfer of interleukin-10 in LDLr-/- mice. FASEB J 2001;15:2730-2
   PubMed Web of Science ®Google Scholar
• Han X, Kitamoto S, Wang H, et al. Interleukin-10 overexpression in macrophages suppresses atherosclerosis in hyperlipidemic mice. FASEB J 2010;24:2869-80
   PubMed Web of Science ®Google Scholar
• Garaulet G, Alfranca A, Torrente M, et al. IL10 released by a new inflammation-regulated lentiviral system efficiently attenuates zymosan-induced arthritis. Mol Ther 2013;21:119-30
   PubMed Web of Science ®Google Scholar
• Loyer X, Potteaux S, Vion AC, et al. Inhibition of microRNA-92a prevents endothelial dysfunction and atherosclerosis in mice. Circ Res 2014;114:434-43
   PubMed Web of Science ®Google Scholar
• Lovren F, Pan Y, Quan A, et al. MicroRNA-145 targeted therapy reduces atherosclerosis. Circulation 2012;126:S81-90
   PubMed Web of Science ®Google Scholar
• Di Gregoli K, Jenkins N, Salter R, et al. MicroRNA-24 regulates macrophage behavior and retards atherosclerosis. Arterioscler Thromb Vasc Biol 2014;34:1990-2000
   PubMed Web of Science ®Google Scholar
• Getz GS, Reardon CA. Animal models of atherosclerosis. Arterioscler Thromb Vasc Biol 2012;32:1104-15
   PubMed Web of Science ®Google Scholar
• Piedrahita JA, Zhang SH, Hagaman JR, et al. Generation of mice carrying a mutant apolipoprotein E gene inactivated by gene targeting in embryonic stem cells. Proc Natl Acad Sci USA 1992;89:4471-5
   PubMed Web of Science ®Google Scholar
• Plump AS, Smith JD, Hayek T, et al. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell 1992;71:343-53
   PubMed Web of Science ®Google Scholar
• Ishibashi S, Brown MS, Goldstein JL, et al. Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery. J Clin Invest 1993;92:883-93
   PubMed Web of Science ®Google Scholar
• Ishibashi S, Herz J, Maeda N, et al. The two-receptor model of lipoprotein clearance: tests of the hypothesis in “knockout” mice lacking the low density lipoprotein receptor, apolipoprotein E, or both proteins. Proc Natl Acad Sci USA 1994;91:4431-5
   PubMed Web of Science ®Google Scholar
• Veniant MM, Zlot CH, Walzem RL, et al. Lipoprotein clearance mechanisms in LDL receptor-deficient “Apo-B48-only” and “Apo-B100-only” mice. J Clin Invest 1998;102:1559-68
   PubMed Web of Science ®Google Scholar
• Leppanen P, Luoma JS, Hofker MH, et al. Characterization of atherosclerotic lesions in apo E3-leiden transgenic mice. Atherosclerosis 1998;136:147-52
   PubMed Web of Science ®Google Scholar
• Hofker MH, van Vlijmen BJ, Havekes LM. Transgenic mouse models to study the role of APOE in hyperlipidemia and atherosclerosis. Atherosclerosis 1998;137:1-11
   PubMed Web of Science ®Google Scholar
• Pendse AA, Arbones-Mainar JM, Johnson LA, et al. Apolipoprotein E knock-out and knock-in mice: atherosclerosis, metabolic syndrome, and beyond. J Lipid Res 2009;50 Suppl:S178-82
   Google Scholar
• Masucci-Magoulas L, Goldberg IJ, Bisgaier CL, et al. A mouse model with features of familial combined hyperlipidemia. Science 1997;275:391-4
   PubMed Web of Science ®Google Scholar
• de Vries-van der Weij J, Zadelaar S, Toet K, et al. Human CETP aggravates atherosclerosis by increasing VLDL-cholesterol rather than by decreasing HDL-cholesterol in APOE*3-Leiden mice. Atherosclerosis 2009;206:153-8
   PubMed Web of Science ®Google Scholar
• Linton MF, Farese RVJr, Chiesa G, et al. Transgenic mice expressing high plasma concentrations of human apolipoprotein B100 and lipoprotein(a). J Clin Invest 1993;92:3029-37
   PubMed Web of Science ®Google Scholar
• Van Herck JL, De Meyer GR, Martinet W, et al. Impaired fibrillin-1 function promotes features of plaque instability in apolipoprotein E-deficient mice. Circulation 2009;120:2478-87
   PubMed Web of Science ®Google Scholar
• Van der Donckt C, Van Herck JL, Schrijvers DM, et al. Elastin fragmentation in atherosclerotic mice leads to intraplaque neovascularization, plaque rupture, myocardial infarction, stroke, and sudden death. Eur Heart J 2015;36:1049-58
   PubMed Web of Science ®Google Scholar
• Kobayashi T, Ito T, Shiomi M. Roles of the WHHL rabbit in translational research on hypercholesterolemia and cardiovascular diseases. J Biomed Biotechnol 2011;2011:406473
   PubMedGoogle Scholar
• Duff GL. Experimental cholesterol arteriosclerosis and its relationship to human atherosclerosis. Arch Pathol 1935;20:81-123
   Google Scholar
• Rekhter MD, Hicks GW, Brammer DW, et al. Animal model that mimics atherosclerotic plaque rupture. Circ Res 1998;83:705-13
   PubMed Web of Science ®Google Scholar
• Abela GS, Picon PD, Friedl SE, et al. Triggering of plaque disruption and arterial thrombosis in an atherosclerotic rabbit model. Circulation 1995;91:776-84
   PubMed Web of Science ®Google Scholar
• Watanabe Y. Serial inbreeding of rabbits with hereditary hyperlipidemia (WHHL-rabbit). Atherosclerosis 1980;36:261-8
   PubMed Web of Science ®Google Scholar
• Bustos C, Hernandez-Presa MA, Ortego M, et al. HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis. J Am Coll Cardiol 1998;32:2057-64
   PubMed Web of Science ®Google Scholar
• Aikawa M, Rabkin E, Voglic SJ, et al. Lipid lowering promotes accumulation of mature smooth muscle cells expressing smooth muscle myosin heavy chain isoforms in rabbit atheroma. Circ Res 1998;83:1015-26
   PubMed Web of Science ®Google Scholar
• Chen WQ, Zhang L, Liu YF, et al. Prediction of atherosclerotic plaque ruptures with high-frequency ultrasound imaging and serum inflammatory markers. Am J Physiol Heart Circ Physiol 2007;293:H2836-44
   Web of Science ®Google Scholar
• Badimon L. Atherosclerosis and thrombosis: lessons from animal models. Thromb Haemost 2001;86:356-65
   PubMed Web of Science ®Google Scholar
• Fuster V, Lie JT, Badimon L, et al. Spontaneous and diet-induced coronary atherosclerosis in normal swine and swine with von Willebrand disease. Arteriosclerosis 1985;5:67-73
   PubMedGoogle Scholar
• Koskinas KC, Feldman CL, Chatzizisis YS, et al. Natural history of experimental coronary atherosclerosis and vascular remodeling in relation to endothelial shear stress: a serial, in vivo intravascular ultrasound study. Circulation 2010;121:2092-101
   PubMed Web of Science ®Google Scholar
• Ikeno F, Buchbinder M, Yeung AC. Novel stent and delivery systems for the treatment of bifurcation lesions: porcine coronary artery model. Cardiovasc Revasc Med 2007;8:38-42
   PubMedGoogle Scholar
• Gerrity RG, Natarajan R, Nadler JL, et al. Diabetes-induced accelerated atherosclerosis in swine. Diabetes 2001;50:1654-65
   PubMed Web of Science ®Google Scholar
• Prescott MF, McBride CH, Hasler-Rapacz J, et al. Development of complex atherosclerotic lesions in pigs with inherited hyper-LDL cholesterolemia bearing mutant alleles for apolipoprotein B. Am J Pathol 1991;139:139-47
   PubMed Web of Science ®Google Scholar
• Davis BT, Wang XJ, Rohret JA, et al. Targeted disruption of LDLR causes hypercholesterolemia and atherosclerosis in Yucatan miniature pigs. PLoS ONE 2014;9:e93457
   Google Scholar
• Al-Mashhadi RH, Sorensen CB, Kragh PM, et al. Familial hypercholesterolemia and atherosclerosis in cloned minipigs created by DNA transposition of a human PCSK9 gain-of-function mutant. Sci Transl Med 2013;5:166ra1
   PubMed Web of Science ®Google Scholar
• Gene Therapy Clinical Trials Worldwide. Vectors Used in Gene Therapy Clinical Trials. The Journal of Gene Medicine. 2015. Available at www.abedia.com/wiley/vectors.php [Last accessed 3 July 2015]
   Google Scholar
• Liu Q, Muruve DA. Molecular basis of the inflammatory response to adenovirus vectors. Gene Ther 2003;10:935-40
   PubMed Web of Science ®Google Scholar
• Kochanek S, Schiedner G, Volpers C. High-capacity ’gutless’ adenoviral vectors. Curr Opin Mol Ther 2001;3:454-63
   PubMed Web of Science ®Google Scholar
• Brunetti-Pierri N, Palmer DJ, Beaudet AL, et al. Acute toxicity after high-dose systemic injection of helper-dependent adenoviral vectors into nonhuman primates. Hum Gene Ther 2004;15:35-46
   PubMed Web of Science ®Google Scholar
• Alba R, Bosch A, Chillon M. Gutless adenovirus: last-generation adenovirus for gene therapy. Gene Ther 2005;12(Suppl 1):S18-27
   PubMed Web of Science ®Google Scholar
• Mastrangeli A, Harvey BG, Yao J, et al. “Sero-switch” adenovirus-mediated in vivo gene transfer: circumvention of anti-adenovirus humoral immune defenses against repeat adenovirus vector administration by changing the adenovirus serotype. Hum Gene Ther 1996;7:79-87
   PubMed Web of Science ®Google Scholar
• Borel F, Kay MA, Mueller C. Recombinant AAV as a platform for translating the therapeutic potential of RNA interference. Mol Ther 2014;22:692-701
   PubMed Web of Science ®Google Scholar
• Selot RS, Hareendran S, Jayandharan GR. Developing immunologically inert adeno-associated virus (AAV) vectors for gene therapy: possibilities and limitations. Curr Pharm Biotechnol 2014;14:1072-82
   PubMed Web of Science ®Google Scholar
• Askou AL, Aagaard L, Kostic C, et al. Multigenic lentiviral vectors for combined and tissue-specific expression of miRNA- and protein-based antiangiogenic factors. Mol Ther Methods Clin Dev 2015;2:14064
   PubMedGoogle Scholar
• Brown BD, Cantore A, Annoni A, et al. A microRNA-regulated lentiviral vector mediates stable correction of hemophilia B mice. Blood 2007;110:4144-52
   PubMed Web of Science ®Google Scholar
• Zhang Y, Jiang G, Sauler M, et al. Lung endothelial HO-1 targeting in vivo using lentiviral miRNA regulates apoptosis and autophagy during oxidant injury. FASEB J 2013;27:4041-58
   PubMed Web of Science ®Google Scholar
• Grandchamp N, Altemir D, Philippe S, et al. Hybrid lentivirus-phiC31-int-NLS vector allows site-specific recombination in murine and human cells but induces DNA damage. PLoS ONE 2014;9:e99649
   Google Scholar
• Mannell H, Pircher J, Rathel T, et al. Targeted endothelial gene delivery by ultrasonic destruction of magnetic microbubbles carrying lentiviral vectors. Pharm Res 2012;29:1282-94
   PubMed Web of Science ®Google Scholar
• Turkki V, Schenkwein D, Timonen O, et al. Lentiviral protein transduction with genome-modifying HIV-1 integrase-I-PpoI fusion proteins: studies on specificity and cytotoxicity. Biomed Res Int 2014;2014:379340
   PubMed Web of Science ®Google Scholar
• Bechara C, Sagan S. Cell-penetrating peptides: 20 years later, where do we stand? FEBS Lett 2013;587:1693-702
   PubMed Web of Science ®Google Scholar
• Madge LA, May MJ. Inhibiting proinflammatory NF-kappaB signaling using cell-penetrating NEMO binding domain peptides. Methods Mol Biol 2009;512:209-32
   PubMedGoogle Scholar
• Mallavia B, Recio C, Oguiza A, et al. Peptide inhibitor of NF-kappaB translocation ameliorates experimental atherosclerosis. Am J Pathol 2013;182:1910-21
   PubMed Web of Science ®Google Scholar
• Hamzah J, Kotamraju VR, Seo JW, et al. Specific penetration and accumulation of a homing peptide within atherosclerotic plaques of apolipoprotein E-deficient mice. Proc Natl Acad Sci USA 2011;108:7154-9
   PubMed Web of Science ®Google Scholar
• Olson ES, Whitney MA, Friedman B, et al. In vivo fluorescence imaging of atherosclerotic plaques with activatable cell-penetrating peptides targeting thrombin activity. Integr Biol (Camb) 2012;4:595-605
   PubMed Web of Science ®Google Scholar
• Vasconcelos L, Parn K, Langel U. Therapeutic potential of cell-penetrating peptides. Ther Deliv 2013;4:573-91
   PubMedGoogle Scholar
• Crombez L, Aldrian-Herrada G, Konate K, et al. A new potent secondary amphipathic cell-penetrating peptide for siRNA delivery into mammalian cells. Mol Ther 2009;17:95-103
   PubMed Web of Science ®Google Scholar
• Lehto T, Ezzat K, Langel U. Peptide nanoparticles for oligonucleotide delivery. Prog Mol Biol Transl Sci 2011;104:397-426
   PubMed Web of Science ®Google Scholar
• McCarthy HO, McCaffrey J, McCrudden CM, et al. Development and characterization of self-assembling nanoparticles using a bio-inspired amphipathic peptide for gene delivery. J Control Release 2014;189:141-9
   PubMed Web of Science ®Google Scholar
• Vasconcelos A, Vega E, Perez Y, et al. Conjugation of cell-penetrating peptides with poly(lactic-co-glycolic acid)-polyethylene glycol nanoparticles improves ocular drug delivery. Int J Nanomedicine 2015;10:609-31
   PubMedGoogle Scholar
• Veiman KL, Kunnapuu K, Lehto T, et al. PEG shielded MMP sensitive CPPs for efficient and tumor specific gene delivery in vivo. J Control Release 2015;209:238-47
   PubMed Web of Science ®Google Scholar
• Joseph L, Robinson JG. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition and the future of lipid lowering therapy. Prog Cardiovasc Dis 2015;58(1):19-31
   PubMed Web of Science ®Google Scholar
• Fitzgerald K, Frank-Kamenetsky M, Shulga-Morskaya S, et al. Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial. Lancet 2014;383:60-8
   PubMed Web of Science ®Google Scholar
• Akdim F, Tribble DL, Flaim JD, et al. Efficacy of apolipoprotein B synthesis inhibition in subjects with mild-to-moderate hyperlipidaemia. Eur Heart J 2011;32:2650-9
   PubMed Web of Science ®Google Scholar
• Akdim F, Visser ME, Tribble DL, et al. Effect of mipomersen, an apolipoprotein B synthesis inhibitor, on low-density lipoprotein cholesterol in patients with familial hypercholesterolemia. Am J Cardiol 2010;105:1413-19
   PubMed Web of Science ®Google Scholar
• Raal FJ, Santos RD, Blom DJ, et al. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet 2010;375:998-1006
   PubMed Web of Science ®Google Scholar
• Federal Drug Administration. NDA 203568: Kynamro (mipomersen sodium) Risk Evaluation and Mitigation Strategy. 2014. Available from: www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM337472.pdf [Last accessed 3 July 2015]
   Google Scholar
• Tekmira pharmaceuticals completes ApoB SNALP Phase 1 Clinical Trial [press release]. 2010. Available from: http://www.marketwired.com/press-release/Tekmira-Pharmaceuticals-Completes-ApoB-SNALP-Phase-1-Clinical-Trial-1098988.htm [Last accessed 3 July 2015]
   Google Scholar
• Gaudet D, Brisson D, Tremblay K, et al. Targeting APOC3 in the familial chylomicronemia syndrome. N Engl J Med 2014;371:2200-6
   PubMed Web of Science ®Google Scholar
• Rognoni A, Cavallino C, Lupi A, et al. Novel biomarkers in the diagnosis of acute coronary syndromes: the role of circulating miRNAs. Expert Rev Cardiovasc Ther 2014;12:1119-24
   PubMed Web of Science ®Google Scholar
• Jiang Y, Wang HY, Li Y, et al. Peripheral blood miRNAs as a biomarker for chronic cardiovascular diseases. Sci Rep 2014;4:5026
   PubMedGoogle Scholar
• Janssen HL, Reesink HW, Lawitz EJ, et al. Treatment of HCV infection by targeting microRNA. N Engl J Med 2013;368:1685-94
   PubMed Web of Science ®Google Scholar
• Ling H, Fabbri M, Calin GA. MicroRNAs and other non-coding RNAs as targets for anticancer drug development. Nat Rev Drug Discov 2013;12:847-65
   PubMed Web of Science ®Google Scholar
• Stone NJ, Robinson JG, Lichtenstein A. The new cholesterol treatment guidelines. N Engl J Med 2014;370:1957
   PubMed Web of Science ®Google Scholar
• Yla-Herttuala S. Endgame: glybera finally recommended for approval as the first gene therapy drug in the European Union. Mol Ther 2012;20:1831-2
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. 2012.Refusal of the marketing authorization for Kynamro (mipomersen). Available from: www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisation/human/002429/WC500136279.pdf [Last accessed 3 July 2015]
   Google Scholar
• Robinson JG, Farnier M, Krempf M, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med 2015;372:1489-99
   PubMed Web of Science ®Google Scholar
• Stein EA, Honarpour N, Wasserman SM, et al. Effect of the proprotein convertase subtilisin/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia. Circulation 2013;128:2113-20
   PubMed Web of Science ®Google Scholar
• Vandenbroucke RE, Libert C. Is there new hope for therapeutic matrix metalloproteinase inhibition? Nat Rev Drug Discov 2014;13:904-27
   PubMed Web of Science ®Google Scholar
• Chan JM, Monaco C, Wylezinska-Arridge M, et al. Imaging of the vulnerable carotid plaque: biological targeting of inflammation in atherosclerosis using iron oxide particles and MRI. Eur J Vasc Endovasc Surg 2014;47:462-9
   PubMed Web of Science ®Google Scholar
• Cong L, Ran FA, Cox D, et al. Multiplex genome engineering using CRISPR/Cas systems. Science 2013;339:819-23
   PubMed Web of Science ®Google Scholar